he number of complaints filed in the U.K. against drug makers over marketing infractions jumped substantially last year, according to the latest figures compiled by an industry-sponsored watchdog.

Overall, 76 complaints were registered in 2016, a 40 percent rise from the 54 that were filed in the previous year and, notably, there was a 30 percent jump in the most serious type of complaint — violations that discredit the entire industry. Many of the largest drug makers made this list. In addition, the number of individual allegations contained in each complaint reviewed was 420 last year, up from 198 in 2015.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that the lead-in graphic seemed to be presage the results – something to make the industry ‘BLUE?’ And if I may not, sadly I already have – Cheers!

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy